Adherence to oral anticancer chemotherapy: What influences patients’ over or non-adherence? Analysis of the OCTO study through quantitative–qualitative methods View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2015-07-04

AUTHORS

Aurélie Bourmaud, Emilie Henin, Fabien Tinquaut, Véronique Regnier, Chloé Hamant, Olivier Colomban, Benoit You, Florence Ranchon, Jérôme Guitton, Pascal Girard, Gilles Freyer, Michel Tod, Catherine Rioufol, Véronique Trillet-Lenoir, Franck Chauvin

ABSTRACT

BackgroundNumerous oral anticancer chemotherapies are available. Non-adherence or over-adherence to these chemotherapies can lead to lowered efficacy and increased risk of adverse events. The objective of this study was to identify patients’ adherence profiles using a qualitative–quantitative method.MethodsA capecitabine treatment was initiated for 38 patients with advanced breast or colorectal cancer. At inclusion, information on patients’ beliefs was reported using a questionnaire. Later, Information on patients’ relation to treatment was obtained from a sub-group during an interview with a sociologist. Questionnaires were analyzed using Multiple Classification Analysis to cluster patients. Treatment adherence was evaluated by an electronic medication event monitoring systems (MEMS caps) and then correlated with patient clusters. Interviews were analyzed to complete and explain results.Results38 patients were enrolled between 2008 and 2011 and completed the questionnaire. Twenty had adherence measured with MEMS caps all along treatment. Between 4 and 6 months after inclusion, 16 patients were interviewed. Patient profile B (retired, with a regular life, surrounded by a relative’s attention to drug adherence, with a low educational level) was statistically associated with adequate adherence (p = 0.049). A tendency for lower adherence was observed among more highly educated patients with an irregular, active life (NS). All patients taking capecitabine demonstrated a risk of over-adherence, potentiating side effects.ConclusionsThese encouraging primary results suggest that further studies should be undertaken and that educational programs tailored to patient profiles should be evaluated to enhance adherence for those who need it and to empower all patients to manage treatment side effects. More... »

PAGES

291

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13104-015-1231-8

DOI

http://dx.doi.org/10.1186/s13104-015-1231-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1034594045

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26142140


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimetabolites, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Capecitabine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colorectal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Medication Adherence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Qualitative Research", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Public Health Department, Hyg\u00e9e Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, 42 270, Saint Priest en Jarez, France", 
          "id": "http://www.grid.ac/institutes/grid.7429.8", 
          "name": [
            "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France", 
            "Public Health Department, Hyg\u00e9e Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, 42 270, Saint Priest en Jarez, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bourmaud", 
        "givenName": "Aur\u00e9lie", 
        "id": "sg:person.0712122560.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0712122560.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.7849.2", 
          "name": [
            "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Henin", 
        "givenName": "Emilie", 
        "id": "sg:person.01033714476.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033714476.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Public Health Department, Hyg\u00e9e Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, 42 270, Saint Priest en Jarez, France", 
          "id": "http://www.grid.ac/institutes/grid.7429.8", 
          "name": [
            "Public Health Department, Hyg\u00e9e Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, 42 270, Saint Priest en Jarez, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tinquaut", 
        "givenName": "Fabien", 
        "id": "sg:person.0644007360.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644007360.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Public Health Department, Hyg\u00e9e Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, 42 270, Saint Priest en Jarez, France", 
          "id": "http://www.grid.ac/institutes/grid.7429.8", 
          "name": [
            "Public Health Department, Hyg\u00e9e Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, 42 270, Saint Priest en Jarez, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Regnier", 
        "givenName": "V\u00e9ronique", 
        "id": "sg:person.0653777465.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653777465.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Public Health Department, Hyg\u00e9e Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, 42 270, Saint Priest en Jarez, France", 
          "id": "http://www.grid.ac/institutes/grid.7429.8", 
          "name": [
            "Public Health Department, Hyg\u00e9e Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, 42 270, Saint Priest en Jarez, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hamant", 
        "givenName": "Chlo\u00e9", 
        "id": "sg:person.0722112665.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722112665.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.7849.2", 
          "name": [
            "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Colomban", 
        "givenName": "Olivier", 
        "id": "sg:person.01125155725.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125155725.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Department, Teaching Hospital, Lyon-Sud University, Lyon, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France", 
            "Medical Oncology Department, Teaching Hospital, Lyon-Sud University, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "You", 
        "givenName": "Benoit", 
        "id": "sg:person.0653052265.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653052265.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oncologic Pharmaceutical Department, Lyon-Sud University Teaching Hospital, Lyon, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France", 
            "Oncologic Pharmaceutical Department, Lyon-Sud University Teaching Hospital, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ranchon", 
        "givenName": "Florence", 
        "id": "sg:person.01173517743.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173517743.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pharmacology-Toxicology Laboratory, Hospices Civils de Lyon, South Biology Center, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.413852.9", 
          "name": [
            "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France", 
            "Pharmacology-Toxicology Laboratory, Hospices Civils de Lyon, South Biology Center, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Guitton", 
        "givenName": "J\u00e9r\u00f4me", 
        "id": "sg:person.0651232245.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651232245.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.7849.2", 
          "name": [
            "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Girard", 
        "givenName": "Pascal", 
        "id": "sg:person.012661201622.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012661201622.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Department, Teaching Hospital, Lyon-Sud University, Lyon, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France", 
            "Medical Oncology Department, Teaching Hospital, Lyon-Sud University, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Freyer", 
        "givenName": "Gilles", 
        "id": "sg:person.0636233052.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636233052.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.7849.2", 
          "name": [
            "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tod", 
        "givenName": "Michel", 
        "id": "sg:person.0763711421.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0763711421.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oncologic Pharmaceutical Department, Lyon-Sud University Teaching Hospital, Lyon, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France", 
            "Oncologic Pharmaceutical Department, Lyon-Sud University Teaching Hospital, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rioufol", 
        "givenName": "Catherine", 
        "id": "sg:person.01301001714.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301001714.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Department, Teaching Hospital, Lyon-Sud University, Lyon, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France", 
            "Medical Oncology Department, Teaching Hospital, Lyon-Sud University, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Trillet-Lenoir", 
        "givenName": "V\u00e9ronique", 
        "id": "sg:person.01352404762.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352404762.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Jean Monnet University, Saint-Etienne, France", 
          "id": "http://www.grid.ac/institutes/grid.6279.a", 
          "name": [
            "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France", 
            "Public Health Department, Hyg\u00e9e Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, 42 270, Saint Priest en Jarez, France", 
            "Jean Monnet University, Saint-Etienne, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chauvin", 
        "givenName": "Franck", 
        "id": "sg:person.01035013747.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01035013747.60"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10549-009-0366-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032462874", 
          "https://doi.org/10.1007/s10549-009-0366-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00520-010-0927-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041708807", 
          "https://doi.org/10.1007/s00520-010-0927-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002280050077", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027739420", 
          "https://doi.org/10.1007/s002280050077"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13187-013-0511-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036647518", 
          "https://doi.org/10.1007/s13187-013-0511-z"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-07-04", 
    "datePublishedReg": "2015-07-04", 
    "description": "BackgroundNumerous oral anticancer chemotherapies are available. Non-adherence or over-adherence to these chemotherapies can lead to lowered efficacy and increased risk of adverse events. The objective of this study was to identify patients\u2019 adherence profiles using a qualitative\u2013quantitative method.MethodsA capecitabine treatment was initiated for 38 patients with advanced breast or colorectal cancer. At inclusion, information on patients\u2019 beliefs was reported using a questionnaire. Later, Information on patients\u2019 relation to treatment was obtained from a sub-group during an interview with a sociologist. Questionnaires were analyzed using Multiple Classification Analysis to cluster patients. Treatment adherence was evaluated by an electronic medication event monitoring systems (MEMS caps) and then correlated with patient clusters. Interviews were analyzed to complete and explain results.Results38 patients were enrolled between 2008 and 2011 and completed the questionnaire. Twenty had adherence measured with MEMS caps all along treatment. Between 4 and 6\u00a0months after inclusion, 16 patients were interviewed. Patient profile B (retired, with a regular life, surrounded by a relative\u2019s attention to drug adherence, with a low educational level) was statistically associated with adequate adherence (p\u00a0=\u00a00.049). A tendency for lower adherence was observed among more highly educated patients with an irregular, active life (NS). All patients taking capecitabine demonstrated a risk of over-adherence, potentiating side effects.ConclusionsThese encouraging primary results suggest that further studies should be undertaken and that educational programs tailored to patient profiles should be evaluated to enhance adherence for those who need it and to empower all patients to manage treatment side effects.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s13104-015-1231-8", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1039457", 
        "issn": [
          "1756-0500"
        ], 
        "name": "BMC Research Notes", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "8"
      }
    ], 
    "keywords": [
      "side effects", 
      "electronic Medication Event Monitoring System", 
      "Medication Event Monitoring System", 
      "anticancer chemotherapy", 
      "treatment side effects", 
      "Event Monitoring System", 
      "advanced breast", 
      "capecitabine treatment", 
      "adverse events", 
      "colorectal cancer", 
      "treatment adherence", 
      "adequate adherence", 
      "patients' beliefs", 
      "low adherence", 
      "patient profiles", 
      "patients", 
      "patient clusters", 
      "adherence profiles", 
      "chemotherapy", 
      "adherence", 
      "Further studies", 
      "treatment", 
      "questionnaire", 
      "risk", 
      "active life", 
      "multiple classification analysis", 
      "profile B", 
      "educational programs", 
      "capecitabine", 
      "cancer", 
      "breast", 
      "months", 
      "efficacy", 
      "study", 
      "interviews", 
      "effect", 
      "primary results", 
      "profile", 
      "inclusion", 
      "octo", 
      "life", 
      "classification analysis", 
      "events", 
      "analysis", 
      "quantitative-qualitative method", 
      "objective", 
      "beliefs", 
      "results", 
      "program", 
      "information", 
      "qualitative-quantitative method", 
      "method", 
      "tendency", 
      "monitoring system", 
      "relation", 
      "system", 
      "clusters", 
      "sociologists", 
      "MEMS"
    ], 
    "name": "Adherence to oral anticancer chemotherapy: What influences patients\u2019 over or non-adherence? Analysis of the OCTO study through quantitative\u2013qualitative methods", 
    "pagination": "291", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1034594045"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13104-015-1231-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26142140"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13104-015-1231-8", 
      "https://app.dimensions.ai/details/publication/pub.1034594045"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:40", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_658.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s13104-015-1231-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13104-015-1231-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13104-015-1231-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13104-015-1231-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13104-015-1231-8'


 

This table displays all metadata directly associated to this object as RDF triples.

304 TRIPLES      21 PREDICATES      101 URIs      88 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13104-015-1231-8 schema:about N7ef0b5e36c3a445686a9ea50fc4ff28b
2 N84676555d2b24c6ab5ebfbc4be3b1d99
3 N867c68a891414d019e8a12a0c6d22c93
4 Nb2d88e2a2a734b348019526477bdab19
5 Nb5876e4562db47ea8b4b67a18a4b826d
6 Nb6de261c4f9b43c9ad71b67bd1cb0c26
7 Nc7068e8fdf8c42b589e54186f6d40189
8 Nd5985354de874745b0d5cd7c2414785f
9 Ndc7326c4d50e4c12a9cffdf259f06503
10 Ne2c0781b3891412283eacfbe7ecfdbac
11 Nf1248e2b682e4e8eb3230052628c4043
12 Nf4d02b2e673d4aeb8aecbb88ac576759
13 anzsrc-for:11
14 anzsrc-for:1112
15 anzsrc-for:1117
16 schema:author Ne94e875f4bbf486aaf6bcde590351da4
17 schema:citation sg:pub.10.1007/s002280050077
18 sg:pub.10.1007/s00520-010-0927-5
19 sg:pub.10.1007/s10549-009-0366-5
20 sg:pub.10.1007/s13187-013-0511-z
21 schema:datePublished 2015-07-04
22 schema:datePublishedReg 2015-07-04
23 schema:description BackgroundNumerous oral anticancer chemotherapies are available. Non-adherence or over-adherence to these chemotherapies can lead to lowered efficacy and increased risk of adverse events. The objective of this study was to identify patients’ adherence profiles using a qualitative–quantitative method.MethodsA capecitabine treatment was initiated for 38 patients with advanced breast or colorectal cancer. At inclusion, information on patients’ beliefs was reported using a questionnaire. Later, Information on patients’ relation to treatment was obtained from a sub-group during an interview with a sociologist. Questionnaires were analyzed using Multiple Classification Analysis to cluster patients. Treatment adherence was evaluated by an electronic medication event monitoring systems (MEMS caps) and then correlated with patient clusters. Interviews were analyzed to complete and explain results.Results38 patients were enrolled between 2008 and 2011 and completed the questionnaire. Twenty had adherence measured with MEMS caps all along treatment. Between 4 and 6 months after inclusion, 16 patients were interviewed. Patient profile B (retired, with a regular life, surrounded by a relative’s attention to drug adherence, with a low educational level) was statistically associated with adequate adherence (p = 0.049). A tendency for lower adherence was observed among more highly educated patients with an irregular, active life (NS). All patients taking capecitabine demonstrated a risk of over-adherence, potentiating side effects.ConclusionsThese encouraging primary results suggest that further studies should be undertaken and that educational programs tailored to patient profiles should be evaluated to enhance adherence for those who need it and to empower all patients to manage treatment side effects.
24 schema:genre article
25 schema:isAccessibleForFree true
26 schema:isPartOf N3995d0345e4e437783168e5d5a981bad
27 Nf920eb546d9b4b419e5356d2b7d6a95b
28 sg:journal.1039457
29 schema:keywords Event Monitoring System
30 Further studies
31 MEMS
32 Medication Event Monitoring System
33 active life
34 adequate adherence
35 adherence
36 adherence profiles
37 advanced breast
38 adverse events
39 analysis
40 anticancer chemotherapy
41 beliefs
42 breast
43 cancer
44 capecitabine
45 capecitabine treatment
46 chemotherapy
47 classification analysis
48 clusters
49 colorectal cancer
50 educational programs
51 effect
52 efficacy
53 electronic Medication Event Monitoring System
54 events
55 inclusion
56 information
57 interviews
58 life
59 low adherence
60 method
61 monitoring system
62 months
63 multiple classification analysis
64 objective
65 octo
66 patient clusters
67 patient profiles
68 patients
69 patients' beliefs
70 primary results
71 profile
72 profile B
73 program
74 qualitative-quantitative method
75 quantitative-qualitative method
76 questionnaire
77 relation
78 results
79 risk
80 side effects
81 sociologists
82 study
83 system
84 tendency
85 treatment
86 treatment adherence
87 treatment side effects
88 schema:name Adherence to oral anticancer chemotherapy: What influences patients’ over or non-adherence? Analysis of the OCTO study through quantitative–qualitative methods
89 schema:pagination 291
90 schema:productId N65b102d81d344f0b856b3e308a571612
91 Nc673071592cf43998a509aba2107e1ed
92 Ne00fa4d1240b47779fce75cfac4ab809
93 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034594045
94 https://doi.org/10.1186/s13104-015-1231-8
95 schema:sdDatePublished 2022-10-01T06:40
96 schema:sdLicense https://scigraph.springernature.com/explorer/license/
97 schema:sdPublisher Nae36829baa3845f6a9cb308e7ea5b33f
98 schema:url https://doi.org/10.1186/s13104-015-1231-8
99 sgo:license sg:explorer/license/
100 sgo:sdDataset articles
101 rdf:type schema:ScholarlyArticle
102 N195c17c75a1f46c28fb363929c282959 rdf:first sg:person.01173517743.97
103 rdf:rest N5f41fe0ae0ae46bda50f1aee129ff7b3
104 N3995d0345e4e437783168e5d5a981bad schema:volumeNumber 8
105 rdf:type schema:PublicationVolume
106 N3b0acdd13e2d4c0494e74805268c618d rdf:first sg:person.0653777465.70
107 rdf:rest N7f34308acb4a40fb8d5c15eaf0ad43ef
108 N41f62b7818704338b85849798f39f9e2 rdf:first sg:person.01301001714.70
109 rdf:rest N919f47a54d8b4eafac6f8fdaa5d7c3fe
110 N4c14c1578e8e4cbeb3e58b590cdc3eff rdf:first sg:person.0653052265.95
111 rdf:rest N195c17c75a1f46c28fb363929c282959
112 N5f41fe0ae0ae46bda50f1aee129ff7b3 rdf:first sg:person.0651232245.54
113 rdf:rest Nb0f8b099b6924bc28ba244bc688482aa
114 N6166e537d2a0465988d6371ecd13a467 rdf:first sg:person.01125155725.09
115 rdf:rest N4c14c1578e8e4cbeb3e58b590cdc3eff
116 N65b102d81d344f0b856b3e308a571612 schema:name dimensions_id
117 schema:value pub.1034594045
118 rdf:type schema:PropertyValue
119 N6baf99c260c041c2ab514b7be1f18307 rdf:first sg:person.01035013747.60
120 rdf:rest rdf:nil
121 N74013cb30846442e811356bb3bdfc06d rdf:first sg:person.0636233052.33
122 rdf:rest Ncdadb350b105434db0dc5fb4c0c5f1d4
123 N7ef0b5e36c3a445686a9ea50fc4ff28b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Capecitabine
125 rdf:type schema:DefinedTerm
126 N7f34308acb4a40fb8d5c15eaf0ad43ef rdf:first sg:person.0722112665.51
127 rdf:rest N6166e537d2a0465988d6371ecd13a467
128 N84676555d2b24c6ab5ebfbc4be3b1d99 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Follow-Up Studies
130 rdf:type schema:DefinedTerm
131 N867c68a891414d019e8a12a0c6d22c93 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Medication Adherence
133 rdf:type schema:DefinedTerm
134 N919f47a54d8b4eafac6f8fdaa5d7c3fe rdf:first sg:person.01352404762.56
135 rdf:rest N6baf99c260c041c2ab514b7be1f18307
136 Nae36829baa3845f6a9cb308e7ea5b33f schema:name Springer Nature - SN SciGraph project
137 rdf:type schema:Organization
138 Nb0f8b099b6924bc28ba244bc688482aa rdf:first sg:person.012661201622.56
139 rdf:rest N74013cb30846442e811356bb3bdfc06d
140 Nb2d88e2a2a734b348019526477bdab19 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Male
142 rdf:type schema:DefinedTerm
143 Nb5876e4562db47ea8b4b67a18a4b826d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Middle Aged
145 rdf:type schema:DefinedTerm
146 Nb6de261c4f9b43c9ad71b67bd1cb0c26 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Female
148 rdf:type schema:DefinedTerm
149 Nc673071592cf43998a509aba2107e1ed schema:name doi
150 schema:value 10.1186/s13104-015-1231-8
151 rdf:type schema:PropertyValue
152 Nc7068e8fdf8c42b589e54186f6d40189 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Breast Neoplasms
154 rdf:type schema:DefinedTerm
155 Ncdadb350b105434db0dc5fb4c0c5f1d4 rdf:first sg:person.0763711421.46
156 rdf:rest N41f62b7818704338b85849798f39f9e2
157 Nd5985354de874745b0d5cd7c2414785f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Colorectal Neoplasms
159 rdf:type schema:DefinedTerm
160 Ndc7326c4d50e4c12a9cffdf259f06503 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Antimetabolites, Antineoplastic
162 rdf:type schema:DefinedTerm
163 Ndefd245b78b8438487bd60533a3a90f6 rdf:first sg:person.01033714476.41
164 rdf:rest Nf2e98659c0e048a2b0f6fa50d3aafb33
165 Ne00fa4d1240b47779fce75cfac4ab809 schema:name pubmed_id
166 schema:value 26142140
167 rdf:type schema:PropertyValue
168 Ne2c0781b3891412283eacfbe7ecfdbac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Aged
170 rdf:type schema:DefinedTerm
171 Ne94e875f4bbf486aaf6bcde590351da4 rdf:first sg:person.0712122560.89
172 rdf:rest Ndefd245b78b8438487bd60533a3a90f6
173 Nf1248e2b682e4e8eb3230052628c4043 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Qualitative Research
175 rdf:type schema:DefinedTerm
176 Nf2e98659c0e048a2b0f6fa50d3aafb33 rdf:first sg:person.0644007360.97
177 rdf:rest N3b0acdd13e2d4c0494e74805268c618d
178 Nf4d02b2e673d4aeb8aecbb88ac576759 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Humans
180 rdf:type schema:DefinedTerm
181 Nf920eb546d9b4b419e5356d2b7d6a95b schema:issueNumber 1
182 rdf:type schema:PublicationIssue
183 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
184 schema:name Medical and Health Sciences
185 rdf:type schema:DefinedTerm
186 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
187 schema:name Oncology and Carcinogenesis
188 rdf:type schema:DefinedTerm
189 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
190 schema:name Public Health and Health Services
191 rdf:type schema:DefinedTerm
192 sg:journal.1039457 schema:issn 1756-0500
193 schema:name BMC Research Notes
194 schema:publisher Springer Nature
195 rdf:type schema:Periodical
196 sg:person.01033714476.41 schema:affiliation grid-institutes:grid.7849.2
197 schema:familyName Henin
198 schema:givenName Emilie
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033714476.41
200 rdf:type schema:Person
201 sg:person.01035013747.60 schema:affiliation grid-institutes:grid.6279.a
202 schema:familyName Chauvin
203 schema:givenName Franck
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01035013747.60
205 rdf:type schema:Person
206 sg:person.01125155725.09 schema:affiliation grid-institutes:grid.7849.2
207 schema:familyName Colomban
208 schema:givenName Olivier
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125155725.09
210 rdf:type schema:Person
211 sg:person.01173517743.97 schema:affiliation grid-institutes:None
212 schema:familyName Ranchon
213 schema:givenName Florence
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173517743.97
215 rdf:type schema:Person
216 sg:person.012661201622.56 schema:affiliation grid-institutes:grid.7849.2
217 schema:familyName Girard
218 schema:givenName Pascal
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012661201622.56
220 rdf:type schema:Person
221 sg:person.01301001714.70 schema:affiliation grid-institutes:None
222 schema:familyName Rioufol
223 schema:givenName Catherine
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301001714.70
225 rdf:type schema:Person
226 sg:person.01352404762.56 schema:affiliation grid-institutes:None
227 schema:familyName Trillet-Lenoir
228 schema:givenName Véronique
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352404762.56
230 rdf:type schema:Person
231 sg:person.0636233052.33 schema:affiliation grid-institutes:None
232 schema:familyName Freyer
233 schema:givenName Gilles
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636233052.33
235 rdf:type schema:Person
236 sg:person.0644007360.97 schema:affiliation grid-institutes:grid.7429.8
237 schema:familyName Tinquaut
238 schema:givenName Fabien
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644007360.97
240 rdf:type schema:Person
241 sg:person.0651232245.54 schema:affiliation grid-institutes:grid.413852.9
242 schema:familyName Guitton
243 schema:givenName Jérôme
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651232245.54
245 rdf:type schema:Person
246 sg:person.0653052265.95 schema:affiliation grid-institutes:None
247 schema:familyName You
248 schema:givenName Benoit
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653052265.95
250 rdf:type schema:Person
251 sg:person.0653777465.70 schema:affiliation grid-institutes:grid.7429.8
252 schema:familyName Regnier
253 schema:givenName Véronique
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653777465.70
255 rdf:type schema:Person
256 sg:person.0712122560.89 schema:affiliation grid-institutes:grid.7429.8
257 schema:familyName Bourmaud
258 schema:givenName Aurélie
259 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0712122560.89
260 rdf:type schema:Person
261 sg:person.0722112665.51 schema:affiliation grid-institutes:grid.7429.8
262 schema:familyName Hamant
263 schema:givenName Chloé
264 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722112665.51
265 rdf:type schema:Person
266 sg:person.0763711421.46 schema:affiliation grid-institutes:grid.7849.2
267 schema:familyName Tod
268 schema:givenName Michel
269 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0763711421.46
270 rdf:type schema:Person
271 sg:pub.10.1007/s002280050077 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027739420
272 https://doi.org/10.1007/s002280050077
273 rdf:type schema:CreativeWork
274 sg:pub.10.1007/s00520-010-0927-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041708807
275 https://doi.org/10.1007/s00520-010-0927-5
276 rdf:type schema:CreativeWork
277 sg:pub.10.1007/s10549-009-0366-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032462874
278 https://doi.org/10.1007/s10549-009-0366-5
279 rdf:type schema:CreativeWork
280 sg:pub.10.1007/s13187-013-0511-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1036647518
281 https://doi.org/10.1007/s13187-013-0511-z
282 rdf:type schema:CreativeWork
283 grid-institutes:None schema:alternateName Medical Oncology Department, Teaching Hospital, Lyon-Sud University, Lyon, France
284 Oncologic Pharmaceutical Department, Lyon-Sud University Teaching Hospital, Lyon, France
285 schema:name EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France
286 Medical Oncology Department, Teaching Hospital, Lyon-Sud University, Lyon, France
287 Oncologic Pharmaceutical Department, Lyon-Sud University Teaching Hospital, Lyon, France
288 rdf:type schema:Organization
289 grid-institutes:grid.413852.9 schema:alternateName Pharmacology-Toxicology Laboratory, Hospices Civils de Lyon, South Biology Center, Lyon, France
290 schema:name EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France
291 Pharmacology-Toxicology Laboratory, Hospices Civils de Lyon, South Biology Center, Lyon, France
292 rdf:type schema:Organization
293 grid-institutes:grid.6279.a schema:alternateName Jean Monnet University, Saint-Etienne, France
294 schema:name EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France
295 Jean Monnet University, Saint-Etienne, France
296 Public Health Department, Hygée Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, 42 270, Saint Priest en Jarez, France
297 rdf:type schema:Organization
298 grid-institutes:grid.7429.8 schema:alternateName Public Health Department, Hygée Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, 42 270, Saint Priest en Jarez, France
299 schema:name EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France
300 Public Health Department, Hygée Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, 42 270, Saint Priest en Jarez, France
301 rdf:type schema:Organization
302 grid-institutes:grid.7849.2 schema:alternateName EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France
303 schema:name EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France
304 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...